However, this chemokine has paradoxically been associated with improved outcome in patients with the luminal-human epidermal growth factor receptor 2 subtype (Razis et al., 2020), and in patients with HER-2 associated BC (Razis et al., 2012). The gene discussed is ERBB2; the disease is breast cancer.